Reuters
10 Aug 2026, 11:39 UTC · 2h ago
UK green lights Lilly's obesity pill
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
10 Aug 2026, 11:39 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The British medicines regulator has authorised Eli Lilly's oral pill Foundayo for weight management and type 2 diabetes. — Approval of an oral alternative to injectables significantly expands the addressable market and patient accessibility for GLP-1 drugs.
+0.60The UK is the first country in Europe to authorise Foundayo. — First-mover regulatory approval in a major market provides a positive signal for subsequent approvals across the EU.
+0.30Which stocks this story touches
The company received regulatory authorization in the UK for its weight management and diabetes pill.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
2h ago
